¼¼°èÀÇ ½ÉÀüµµ ¸ð´ÏÅ͸µ Àåºñ ½ÃÀå ±Ô¸ð ¹× ¿¹Ãø(2021-2031³â), ¼¼°è ¹× Áö¿ª Á¡À¯À², µ¿Çâ, ¼ºÀå ±âȸ ºÐ¼® º¸°í¼­ : Á¦Ç°º°, ¸®µå À¯Çüº°, ±â¼úº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°
ECG Monitoring Equipment Market Size and Forecast 2021-2031, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product, Lead Type, Technology, End User, and Geography
»óǰÄÚµå : 1780880
¸®¼­Ä¡»ç : The Insight Partners
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 248 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,450 £Ü 6,227,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù.
US $ 6,450 £Ü 9,026,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,450 £Ü 11,824,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

´ç»çÀÇ ÃֽŠÁ¶»ç º¸°í¼­ "½ÉÀüµµ ¸ð´ÏÅ͸µ Àåºñ ½ÃÀå ¿¹Ãø"¿¡ µû¸£¸é, ½ÃÀåÀº 2024³â 61¾ï 9,000¸¸ ´Þ·¯¿¡¼­ 2031³â 86¾ï 8,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2025-2031³â µ¿¾È 5.1%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ½ÉÀüµµ ¸ð´ÏÅ͸µ Àåºñ ½ÃÀåÀÇ ¼ºÀåÀº ½ÉÇ÷°üÁúȯÀÇ À¯º´·ü Áõ°¡, Á¤ºÎÀÇ ³ë·Â°ú ÇコÄɾî ÅõÀÚ ±ÞÁõ¿¡ ±âÀÎÇÕ´Ï´Ù.

½ÉÀüµµ ¸ð´ÏÅ͸µ Àåºñ´Â ½ÉÀåÀÇ Àü±âÀû Ȱµ¿À» ÃøÁ¤ÇÏ´Â µ¥ »ç¿ëµÇ´Â ÀÇ·áÀåºñÀÔ´Ï´Ù. ÀÌ·¯ÇÑ Àåºñ´Â ºÎÁ¤¸Æ, ½ÉÀ帶ºñ, ±âŸ ½ÉÀå ÁúȯÀ» Æ÷ÇÔÇÑ ½ÉÀå Áúȯ Áø´Ü¿¡ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. °¢ ½ÉÀå ¹Úµ¿À» À¯¹ßÇÏ´Â Àü±â ½ÅÈ£¸¦ °¨ÁöÇÏ¿© ½ÉÀå ¸®µë°ú Àü¹ÝÀûÀÎ °Ç°­ »óÅ¿¡ ´ëÇÑ Áß¿äÇÑ Á¤º¸¸¦ Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù.

ºÏ¹Ì ½ÉÀüµµ ¸ð´ÏÅ͸µ Àåºñ ½ÃÀåÀº ¹Ì±¹, ij³ª´Ù, ¸ß½ÃÄÚ·Î ±¸ºÐµË´Ï´Ù. ºÏ¹Ì´Â ½ÃÀå ¼ºÀåÀ» °ßÀÎÇÏ´Â µ¥ ÀÖ¾î ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ·¯ÇÑ ¼ºÀå¿¡ ±â¿©ÇÏ´Â ÁÖ¿ä ¹ßÀü ¿äÀÎÀ¸·Î´Â ½ÉÇ÷°üÁúȯÀÇ À¯º´·ü Áõ°¡, ¿¹¹æ ÀÇ·á¿¡ ´ëÇÑ °ü½É Áõ°¡, Àß Á¤ºñµÈ ÀÇ·á ÀÎÇÁ¶óÀÇ Á¸Àç µîÀ» ²ÅÀ» ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Á¤ºÎ Áö¿ø, Àα¸ °í·ÉÈ­, ½ÉÀå °ü·Ã Áúȯ¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ÀÌ Áö¿ªÀÇ ½ÉÀüµµ ¸ð´ÏÅ͸µ Àåºñ ½ÃÀå È®´ë°¡ ´õ¿í °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. ±â¼úÀÇ ¹ßÀüµµ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. µðÁöÅÐ ½ÉÀüµµ ¸ð´ÏÅ͸µ ÀåºñÀÇ Çõ½ÅÀº Á¤È®¼º, È޴뼺, »ç¿ë ÆíÀǼºÀ» Çâ»ó½ÃÄÑ ÀÇ·áÁø°ú ȯÀÚ ¸ðµÎ¿¡°Ô º¸´Ù Á¢±ÙÇϱ⠽±°í È¿°úÀûÀÏ ¼ö ÀÖµµ·Ï Çϰí ÀÖ½À´Ï´Ù.

ºÏ¹Ì¿¡¼­´Â ¹Ì±¹ÀÌ ½ÉÀüµµ ¸ð´ÏÅ͸µ Àåºñ ½ÃÀå¿¡¼­ Å« ºñÁßÀ» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ¹Ì±¹¿¡¼­´Â ³ëÀÎ Àα¸ÀÇ Áõ°¡, ½ÉÇ÷°üÁúȯÀÇ À¯º´·ü°ú ÀÎÁöµµÀÇ Áõ°¡, ¿¹¹æ ÀÇ·á¿¡ ´ëÇÑ °ü½É Áõ°¡, ÁÖ¿ä ½ÉÀå ÁöÇ¥¸¦ ¸ð´ÏÅ͸µÇÏ´Â ±â¼úÀÇ ¹ßÀü, ¿ø°Ý ¸ð´ÏÅ͸µÀÇ È°¼ºÈ­ µîÀÇ ¿äÀÎÀ¸·Î ÀÎÇØ ½ÉÀüµµ ¸ð´ÏÅ͸µ Àåºñ¿¡ ´ëÇÑ ¼ö¿ä°¡ ƯÈ÷ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¹Ì±¹ Áúº´¿¹¹æÅëÁ¦¼¾ÅÍ(CDC)¿¡ µû¸£¸é, ±¹³»¿¡¼­´Â ¸Å³â 80¸¸ 5,000¸íÀÌ ½ÉÀ帶ºñ¸¦ °æÇèÇϰí ÀÖÀ¸¸ç, ±× Áß 60¸¸ 5,000¸íÀÌ Ã¹ ½ÉÀ帶ºñ¸¦ °æÇèÇϰí ÀÖ½À´Ï´Ù. Million Hearts 2021ÀÇ µ¥ÀÌÅÍ¿¡ µû¸£¸é, ¹Ì±¹¿¡¼­´Â ¿¬°£ 150¸¸ ¸íÀÇ ½É±Ù°æ»ö°ú ³úÁ¹ÁßÀÌ ¹ß»ýÇÕ´Ï´Ù. ¹Ì±¹¿¡¼­ °¡Àå ÈçÇÑ ½ÉÀ庴Àº °ü»óµ¿¸ÆÁúȯ(CAD)ÀÔ´Ï´Ù. CDC 2022 ÃßÁ¤¿¡ µû¸£¸é, ¹Ì±¹ ¼ºÀÎ 2,010¸¸ ¸íÀÌ CAD¸¦ ¾Î°í ÀÖ´Â °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. ºÎÁ¤¸Æ, ½É±Ù°æ»ö, ½ÉºÎÀü µî ´Ù¾çÇÑ ½ÉÀåÁúȯÀÇ Áø´Ü°ú ¸ð´ÏÅ͸µ¿¡ ÇʼöÀûÀÎ ½ÉÀüµµ ¸ð´ÏÅ͸µ Àåºñ´Â CVDÀÇ Á¶±â¹ß°ß, Ä¡·á°èȹ, Àå±âÀûÀÎ °ü¸®¿¡ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù.

¹Ì±¹½ÉÀåÇùȸ¿¡ µû¸£¸é, ¹Ì±¹ ¼ºÀÎÀÇ Àý¹Ý °¡±îÀ̰¡ CVD¸¦ ¾Î°í ÀÖÀ¸¸ç, 2035³â±îÁö ½ÉºÎÀüÀ» ¾Î°í ÀÖ´Â ¼ºÀÎÀÇ ¼ö´Â 40% Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. 2035³â±îÁö ¹Ì±¹ Àα¸ÀÇ 45.1%¿¡ ÇØ´çÇÏ´Â 1¾ï 3,000¸¸ ¸í ÀÌ»óÀÇ ¼ºÀÎÀÌ CVD¸¦ ¾ÎÀ» °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ Àåºñ´Â ºñħ½ÀÀûÀÌ°í ½Å¼ÓÇϸç, °í±Þ ¿µ»ó Áø´Ü ¹× ÀÇ·á °³ÀÔÀÇ Çʿ伺°ú °°Àº Ãß°¡ °ü¸®¸¦ À§ÇÑ ´Ü¼­¸¦ Á¦°øÇÕ´Ï´Ù.

CVD Á¶±â ¹ß°ßÀ» ÃËÁøÇÏ´Â °øÁߺ¸°Ç ³ë·Â°ú ÀÎ½Ä °³¼± Ä·ÆäÀÎÀº ½ÉÀüµµ ¸ð´ÏÅ͸µ ÀåºñÀÇ Ã¤ÅÃÀ» Áõ°¡½ÃŰ°í °øÁߺ¸°ÇÀÇ Àü¹ÝÀûÀÎ ¼º°ú¸¦ Çâ»ó½ÃŰ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, CDCÀÇ ½ÉÀ庴 ¹× ³úÁ¹Áß ¿¹¹æ ºÎ¼­(DHDSP)´Â ½ÉÀ庴 ¹× ³úÁ¹Áß°ú °ü·ÃµÈ À§Çè ¿äÀÎÀ» ¿¹¹æ, °ü¸® ¹× °¨¼Ò½Ã۱â À§ÇØ ÁÖ, Áö¹æ ¹× ºÎÁ· ÁֹεéÀÇ Áúº´ °ü¸®¸¦ µ½°í ÀÖ½À´Ï´Ù. DHDSP¿Í ÇÔ²² ´ç´¢º´ ´ëÃ¥ ºÎ¼­´Â ½ÉÀ庴, ³úÁ¹Áß µîÀÇ °Ç°­ ¹®Á¦¸¦ ÇØ°áÇϱâ À§ÇØ 50°³ ÁÖ¿Í Ä÷³ºñ¾Æ Ưº°±¸¸¦ Áö¿øÇϰí ÀÖ½À´Ï´Ù. ½ÃÀå °³Ã´À» À§ÇØ ½ÃÀå ±â¾÷µéÀº À¯±âÀû, ¹«±âÀû Àü·«µµ äÅÃÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2024³â 12¿ù, ÷´Ü ÀλçÀÌÆ®¸¦ ÅëÇØ ½ÉÀå Ä¡·á¿¡ Çõ¸íÀ» ÀÏÀ¸Å°´Â ¼±±¸ÀûÀÎ ÀÇ·á ±â¼ú ±â¾÷ HeartBeam, Inc.´Â ¹Ì±¹ ½ÄǰÀǾ౹(FDA)ÀÌ Á¾ÇÕÀûÀÎ ºÎÁ¤¸Æ Æò°¡¿¡ ƯȭµÈ HeartBeam ½Ã½ºÅÛ¿¡ ´ëÇØ 510(k) ½ÂÀÎÀ» ºÎ¿©Çß´Ù°í ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ Àåºñ´Â ƯÇã¹ÞÀº µðÀÚÀÎÀÌ Æ¯Â¡À̸ç, ÀÌ Á¾·ùÀÇ Àåºñ Áß ÃÖÃÊ·Î FDAÀÇ ½ÂÀÎÀ» ¹Þ¾Ò½À´Ï´Ù. °íÃæ½Çµµ ½ÉÀüµµ ½Ã½ºÅÛÀ¸·Î¼­ ½Å¿ëÄ«µå Å©±âÀÇ ÄÄÆÑÆ®ÇÑ Å©±â¿Í ÄÉÀ̺íÀÌ ¾ø´Â µðÀÚÀÎÀÌ Æ¯Â¡À̸ç, ¼¼ °¡Áö ´Ù¸¥ °¢µµ¿¡¼­ ½ÉÀå ½ÅÈ£¸¦ È¿°úÀûÀ¸·Î Æ÷ÂøÇÏ¿© ½Ç¿ëÀûÀÎ ½ÉÀå °Ç°­ °ü¸®¸¦ À§ÇÑ Áß¿äÇÑ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ½ÉÀüµµ ¸ð´ÏÅ͸µ ÀåºñÀÇ ¹ßÀüÀº ¹Ì±¹ ½ÃÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

±â¼ú ¹ßÀü°ú ½º¸¶Æ® ¿þ¾î·¯ºíÀÇ ¹ßÀüÀº ÇâÈÄ ½ÃÀå ±âȸ¸¦ °¡Á®¿Ã °ÍÀÔ´Ï´Ù.

Áö¼ÓÀûÀÎ ±â¼ú ¹ßÀü°ú Áö¼ÓÀûÀÎ °Ç°­ ¸ð´ÏÅ͸µ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡´Â ½º¸¶Æ® ½ÉÀüµµ ¿þ¾î·¯ºí ÀåºñÀÇ ±æÀ» ¿­¾îÁÖ°í ÀÖ½À´Ï´Ù. ½º¸¶Æ® ½ÉÀüµµ ¿þ¾î·¯ºí ÀåºñÀÇ Áõ°¡ Ãß¼¼´Â ÁÖ·Î ½ÉÀå °Ç°­ »óŸ¦ ½Ç½Ã°£À¸·Î ¸ð´ÏÅ͸µÇÏ´Â ½ÉÀüµµ ¼¾¼­¿Í ÅëÇÕµÈ ½º¸¶Æ® ¿öÄ¡ ¹× ÇÇÆ®´Ï½º Æ®·¡Ä¿ÀÇ ¼ö¿ëÀÌ È®´ëµÇ°í Àֱ⠶§¹®ÀÔ´Ï´Ù. ¿¹¸¦ µé¾î, Apple Watch Series 4 ÀÌ»ó ¹öÀü¿¡´Â ½É¹æ¼¼µ¿(AFib) ¹× ±âŸ ½ÉÀå ÁúȯÀ» °¨ÁöÇÏ´Â µ¥ µµ¿òÀÌ µÇ´Â FDA ½ÂÀÎ ½ÉÀüµµ ¾ÛÀÌ Å¾ÀçµÇ¾î ÀÖ½À´Ï´Ù. ¸¶Âù°¡Áö·Î Fitbit Sense ½º¸¶Æ®¿öÄ¡¿¡ žÀçµÈ ½ÉÀüµµ ±â´ÉÀ» ÅëÇØ »ç¿ëÀÚ´Â ºÎÁ¤¸ÆÀ» °¨ÁöÇÒ ¼ö ÀÖ½À´Ï´Ù. ½ÉÀüµµ ±â¼úÀ» ¿þ¾î·¯ºí Àåºñ¿¡ Á¢¸ñÇÏ¿© ±âÁ¸ ½ÉÀüµµ °Ë»ç¿Í ´Þ¸® ½ÉÀå °Ç°­ »óŸ¦ Áö¼ÓÀûÀ¸·Î ¸ð´ÏÅ͸µÇÒ ¼ö ÀÖ½À´Ï´Ù. Àå±âÀûÀÎ ¸ð´ÏÅ͸µ¿¡ ´ëÇÑ ±Þ°ÝÇÑ °æ»ç´Â ½ÉÀå ÀÌ»óÀ» Á¶±â¿¡ ¹ß°ßÇÒ ¼ö ÀÖ¾î º´¿ø ¹æ¹®°ú ÀÇ·áºñ ÁöÃâÀ» ÁÙÀÏ ¼ö ÀÖ½À´Ï´Ù. JAMA CardiologyÀÇ º¸°í¼­¿¡ µû¸£¸é, ¿þ¾î·¯ºí ½ÉÀüµµ ¸ð´ÏÅ͸¦ ÅëÇÑ ½ÉÀå ÁúȯÀÇ ¹ß°ßÀº ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±ÇÏ°í »ç¸Á·üÀ» °¨¼Ò½ÃŰ´Â µ¥ µµ¿òÀÌ µÇ´Â °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. ¶ÇÇÑ, ÀΰøÁö´É(AI)ÀÇ ¹ßÀüÀº ÁÖ¿ä ±â¼úÀÇ ¹ßÀü°ú ÇÔ²² ½º¸¶Æ® ½ÉÀüµµ ¿þ¾î·¯ºí Àåºñ¿¡ ´ëÇÑ ¼ö¿ä¸¦ âÃâÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀΰøÁö´É ±â¹Ý ¾Ë°í¸®ÁòÀÌ ½ÉÀüµµ µ¥ÀÌÅ͸¦ ½Ç½Ã°£À¸·Î ºÐ¼®ÇÏ¿© ½É°¢ÇÑ ¹®Á¦·Î ¹ßÀüÇϱâ ÈξÀ Àü¿¡ ½ÉÀå ¹®Á¦¿¡ ´ëÇÑ ¿¹ÃøÀû ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù. Á¤È®µµ Çâ»ó, ºñ¿ë Àý°¨, ¿þ¾î·¯ºí ½ÉÀüµµ¿Í ¿ø°ÝÀÇ·á Ç÷§ÆûÀÇ ÅëÇÕÀº °³ÀÎÈ­µÈ ½ÉÇ÷°ü Ä¡·áÀÇ ½Ã´ë¸¦ ¿­¾î ÇâÈÄ ¸î ³â µ¿¾È ½ÉÀüµµ ¸ð´ÏÅ͸µ Àåºñ ½ÃÀåÀÇ ¼ºÀå¿¡ ±â¿©ÇÒ °ÍÀÔ´Ï´Ù.

¹Ì±¹ ½ÄǰÀǾ౹(FDA), ¹Ì±¹½ÉÀåÇÐȸ(American College Cardiology), Barcelona Institute for Global Health, Our World in data µîÀº ½ÉÀüµµ ¸ð´ÏÅ͸µ Àåºñ ½ÃÀå º¸°í¼­ ÀÛ¼º ½Ã Âü°íÇÑ 1Â÷ Á¤º¸ ¹× 2Â÷ Á¤º¸ÀÇ ÀϺÎÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼Ò°³

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå Á¶»ç ¹æ¹ý

Á¦4Àå ½ÉÀüµµ ¸ð´ÏÅ͸µ Àåºñ ½ÃÀå »óȲ

Á¦5Àå ½ÉÀüµµ ¸ð´ÏÅ͸µ Àåºñ ½ÃÀå : ÁÖ¿ä ½ÃÀå ¿ªÇÐ

Á¦6Àå ½ÉÀüµµ ¸ð´ÏÅ͸µ Àåºñ ½ÃÀå : ¼¼°è ½ÃÀå ºÐ¼®

Á¦7Àå ½ÉÀüµµ ¸ð´ÏÅ͸µ Àåºñ ½ÃÀå ºÐ¼® : Á¦Ç°º°

Á¦8Àå ½ÉÀüµµ ¸ð´ÏÅ͸µ Àåºñ ½ÃÀå ºÐ¼® : ¸®µå À¯Çüº°

Á¦9Àå ½ÉÀüµµ ¸ð´ÏÅ͸µ Àåºñ ½ÃÀå ºÐ¼® : ±â¼úº°

Á¦10Àå ½ÉÀüµµ ¸ð´ÏÅ͸µ Àåºñ ½ÃÀå ºÐ¼® : ÃÖÁ¾»ç¿ëÀÚº°

Á¦11Àå ½ÉÀüµµ ¸ð´ÏÅ͸µ Àåºñ ½ÃÀå ºÐ¼® : Áö¿ªº°

Á¦12Àå °æÀï ±¸µµ

Á¦13Àå ¾÷°è »óȲ

Á¦14Àå ±â¾÷ °³¿ä

Á¦15Àå ºÎ·Ï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

According to our new research study on "ECG Monitoring Equipment Market Forecast to 2031 -Global Analysis - by Product, Lead Type, Technology, End User," the market is anticipated to grow from US$ 6.19 billion in 2024 and is projected to reach US$ 8.68 billion by 2031; it is expected to register a CAGR of 5.1% during 2025-2031. The ECG Monitoring Equipment market growth is attributed to the increasing prevalence of cardiovascular disorders and a surge in government initiatives and healthcare investment.

ECG Monitoring Equipment are medical instruments used to measure the electrical activity of the heart. These devices are crucial for diagnosing heart conditions, including arrhythmia, heart attacks, and other cardiac abnormalities. They detect the electrical signals that trigger each heartbeat and can provide vital information about the heart's rhythm and overall health.

The ECG Monitoring Equipment market in North America is segmented into the US, Canada, and Mexico. The North American region is anticipated to play a pivotal role in driving the market's growth. Key factors contributing to this growth include the increasing incidence of cardiovascular disease, an increased focus on preventive healthcare, and the presence of well-developed healthcare infrastructure. Additionally, government support, an aging population, and growing awareness of heart-related diseases are further propelling the expansion of the ECG Monitoring Equipment market in the region. Technological advancements have also played a crucial role. Innovations in digital ECG Monitoring Equipment have enhanced accuracy, portability, and user-friendliness, making them more accessible and effective for both healthcare providers and patients.

In North America, the US holds a significant share of the ECG Monitoring Equipment market. In the US, the demand for ECG Monitoring Equipment has been particularly strong due to factors such as the rising geriatric population, growing prevalence and awareness of cardiovascular diseases, increasing focus on preventive healthcare, technological advancements in monitoring vital cardiac indicators, and the push for remote monitoring. According to the Centers for Disease Control and Prevention (CDC), ~805,000 people experience a heart attack in the country every year, of which ~605,000 individuals are first-time heart attacks. As per the Million Hearts 2021 data, ~1.5 million myocardial infarctions and strokes occur in the US annually. The most common type of heart disease in the nation is coronary artery disease (CAD). Per the CDC 2022 estimates, 20.1 million US adults report CAD. ECG Monitoring Equipment, which are critical in diagnosing and monitoring various heart conditions such as arrhythmia, heart attack, and heart failure, play a vital role in early detection, treatment planning, and long-term management of CVD.

According to the American Heart Association, nearly half of adults in the US have some type of CVD, and it is estimated that the number of adults suffering from heart failure is projected to increase by 2035 by 40%. By 2035, over 130 million adults, i.e., 45.1% of the US population, are expected to report some form of CVD. These devices are noninvasive, quick, and provide clues to guide further management, such as the need for more advanced imaging or medical interventions.

Public health initiatives and awareness campaigns promoting early detection of CVDs have played a pivotal role in increasing the adoption of ECG Monitoring Equipment and improving overall public health outcomes. For instance, to prevent, manage, and reduce the risk factors associated with heart disease and stroke, the CDC's Division for Heart Disease and Stroke Prevention (DHDSP) supports state, local, and tribal populations in managing the condition. Along with DHDSP, the Division of Diabetes Translation also supports all 50 states and the District of Columbia to address health problems such as heart disease and stroke. Market players are also adopting organic and inorganic strategies for market development. For instance, in December 2024, HeartBeam, Inc., a pioneering medical technology company dedicated to revolutionizing cardiac care through advanced insights, announced that the US Food and Drug Administration (FDA) has granted 510(k) clearance for the HeartBeam system, specifically for comprehensive arrhythmia assessment. This device, distinguished by its patented design, is the first of its kind to achieve FDA approval. As a high-fidelity ECG system featuring a compact, credit card-sized form and a cable-free design, it effectively captures heart signals from three different angles, providing crucial information for actionable heart health management. Such advancements in ECG Monitoring Equipment are promoting its market in the US.

Technological Advancement and Development of Smart Wearables to Provide Market Opportunities in Future

Continuous technological advancement and increasing demand for continuous health monitoring have paved the way for smart ECG wearable devices. The increasing trend toward smart ECG wearable devices is driven mainly by the growing acceptance of smartwatches and fitness trackers integrated with ECG sensors for live heart health monitoring. For instance, Apple Watch Series 4 and later versions have an FDA-approved ECG app which helps in the detection of atrial fibrillation (AFib) and other heart conditions. Similarly, ECG functionality in the Fitbit Sense smartwatch allows users to detect irregular heart rhythms. The integration of ECG technology into wearable devices allows for continuous heart health monitoring, contrary to traditional ECG testing. The surging inclination toward long-term monitoring would allow for the early detection of heart abnormalities, possibly reducing hospital visits and healthcare expenditure. As per the JAMA Cardiology report, the detection of heart conditions via wearable ECG monitors was found to be beneficial in improving the outcome of patients and reducing mortality. Furthermore, the advancement in artificial intelligence (AI), along with key technological progress, is expected to create demand for smart ECG wearable devices. Algorithms based on artificial intelligence will analyze ECG data in real-time to provide predictive insights into problems with the heart long before it can become a significant issue. The increasing accuracy, decreasing costs, and integration of wearable ECG with telehealth platforms will lead to the era of personalized cardiovascular care, contributing to ECG Monitoring Equipment' market growth in the coming years.

The US Food and Drug Administration, American College Cardiology, The Barcelona Institute for Global Health, and Our World in data are among the primary and secondary sources referred to while preparing the ECG Monitoring Equipment market report.

Table Of Contents

1. Introduction

2. Executive Summary

3. Research Methodology

4. ECG Monitoring Equipment Market Landscape

5. ECG Monitoring Equipment Market - Key Market Dynamics

6. ECG Monitoring Equipment Market - Global Market Analysis

7. ECG Monitoring Equipment Market Analysis - by Product

8. ECG Monitoring Equipment Market Analysis - by Lead Type

9. ECG Monitoring Equipment Market Analysis - by Technology

10. ECG Monitoring Equipment Market Analysis - by End User

11. ECG Monitoring Equipment Market - Geographical Analysis

12. Competitive Landscape

13. Industry Landscape

14. Company Profiles

15. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â